Malondialdehyde, carbonyl proteins and albumin-disulphide as useful oxidative markers in mild cognitive impairment and Alzheimer's disease

References

• Katzman R, Saitoh T. Advances in Alzheimer's disease. FASEB J. 1991; 4: 278–286
   Google Scholar
• Cecchi C, Fiorillo C, Sorbi S, Latorraca S, Nacmias B, Bagnoli S, Nassi P, Liguri G. Oxidative stress and reduced antioxidant defences in peripheral cells from familial Alzheimer's patients. Free Radic Biol Med 2002; 33: 1372–1379
   PubMed Web of Science ®Google Scholar
• Perry G, Nunomura A, Hirai K, Zhu X, Perez M, Avila J, Castellani RJ, Atwood CS, Aliev G, Sayre LM, Takeda A, Smith MA. Is oxidative damage the fundamental pathogenic mechanism of Alzheimer's and other neurodegenerative diseases?. Free Radic Biol Med 2002; 33: 1475–1479
   PubMed Web of Science ®Google Scholar
• Smith MA, Perry G, Richey PL, Sayre LM, Anderson VE, Beal MF, Kowall N. Oxidative damage in Alzheimer's. Nature 1996; 382: 120–121
   PubMed Web of Science ®Google Scholar
• Boyd-Kimball D, Castegna A, Sultana R, Fai Poon H, Petroze R, Lynn BC, Klein JB, Butterfield DA. Proteomic identification of proteins oxidized by Aβ(1–42) in synaptosomes: implications for Alzheimer's disease. Brain Res 2005; 1044: 206–215
   PubMed Web of Science ®Google Scholar
• Liu Q, Raina AK, Smith MA, Sayre LM, Perry G. Hydroxynonenal, toxic carbonyls, and Alzheimer disease. Molec Aspects Med 2003; 24: 305–313
   PubMedGoogle Scholar
• Picklo Sr MJ, Montine TJ, Amarnath V, Neely MD. Carbonyl toxicology and Alzheimer's disease. Toxicol Appl Pharmacol 2002; 184: 187–197
   PubMedGoogle Scholar
• Pratico D, Clark CM, Liun F, Rokach J, Lee VY, Trojanowski JQ. Increase of brain oxidative stress in mild cognitive impairment: a possible predictor of Alzheimer disease. Arch Neurol 2002; 59: 972–976
   PubMedGoogle Scholar
• Smith CD, Carney JM, Tatsumo T, Tadtman ER, Floyd RA, Markesbery WR. Protein oxidation in aging brain. Ann NY Acad Sci 1992; 663: 110–119
   PubMed Web of Science ®Google Scholar
• Keller JN, Schmitt FA, Scheff SW, Ding Q, Chen Q, Butterfield DA, Markesbery WR. Eividence of increased oxidative damage in subjects with mild cognitive impairment. Neurology 2005; 64: 1152–1156
   PubMed Web of Science ®Google Scholar
• Sayre LM, Smith MA, Perry G. Chemistry and biochemistry of oxidative stress in neurodegenerative disease. Curr Med Chem 2001; 8: 721–738
   PubMed Web of Science ®Google Scholar
• Volicer M. Free radicals in the development of Alzheimer's disease. Neurobiol Aging 1991; 11: 567–571
   Google Scholar
• Keller JN. Interplay between oxidative damage, protein synthesis, and protein degradation in Alzheimer's disease. J Biomed Biotechnol 2006; 3: 1–3
   Google Scholar
• Cecarini V, Ding Q, Keller JN. Oxidative inactivation of the proteasome in Alzheimer's disease. Free Radic Res 2007; 41: 673–680
   PubMed Web of Science ®Google Scholar
• Pratico D, Sung S. Lipid peroxidation and oxidative imbalance: early functional event in Alzheimer's disease. J Alzheimer Dis 2004; 6: 171–175
   PubMed Web of Science ®Google Scholar
• Markesbery WR, Lovell MA. Damage to lipids, proteins, DNA, and RNA in mild cognitive impairment. Neurol Rev 2007; 64: 954–956
   Google Scholar
• Lovell MA, Markesbery WR. Oxidatively modified RNA in mild cognitive impairment. Neurobiol Dis 2008; 28: 169–175
   Google Scholar
• Ding Q, Markesbery WR, Cecarini V, Keller JN. Decreased RNA, and increased RNA oxidation, in ribosomes from early Alzheimer's disease. Neurochem Res 2006; 31: 705–710
   PubMed Web of Science ®Google Scholar
• Butterfiled DA, Drake J, Pocernich C, Castegna A. Evidence of oxidative damage in Alzheimer's disease brain: central role for amyloid beta-peptide. Trends Mol Med 2001; 7: 548–554
   PubMedGoogle Scholar
• Choi J, Malakowsky CA, Talent JM, Conrad CC, Gracy RW. Identification of oxidized plasma proteins in Alzheimer's disease. Biochem Biophys Res Commun 2002; 293: 1566–1570
   PubMed Web of Science ®Google Scholar
• Conrad CC, Marshall PL, Talent JM, Malakowsky CA, Choi J, Gracy RW. Oxidized proteins in Alzheimer's plasma. Biochem Biophys Res Commun 2000; 275: 678–681
   PubMed Web of Science ®Google Scholar
• Beal MF. Oxidatively modified proteins in aging and disease. Free Radic Biol Med 2002; 32: 797–803
   PubMed Web of Science ®Google Scholar
• Smith MA, Harris PLR, Sayre LM, Beckham JS, Perry G. Widespread peroxynitrite-mediated damage in Alzheimer's disease. J Neurosci 1997; 17: 2653–2657
   PubMed Web of Science ®Google Scholar
• Esterbauer H, Schaur J, Zollner H. Chemistry and biochemistry of 4-hydroxynonenal, malondialdehyde, and related aldehydes. Free Radic Biol Med 1991; 11: 81–128
   PubMed Web of Science ®Google Scholar
• Harman D. Free radical theory of aging: Alzheimer's disease pathogenesis. Age 1995; 18: 97–119
   Web of Science ®Google Scholar
• Lovell MA, Ehmann WD, Butler SM, Markesbery WR. Elevated thiobarbituric acid-reactive substances and antioxidant enzyme activity in the brain in Alzheimer's disease and aging. Neurology 1995; 45: 1594–1601
   PubMed Web of Science ®Google Scholar
• Seidler NW., Yeargans GS. Albumin-bound polyacrolein: implications for Alzheimer's disease. Biochem Biophys Res Commun 2004; 320: 213–217
   PubMedGoogle Scholar
• Himmelfarb J, McMonagle E. Albumin is the major plasma protein target of oxidant stress in uremia. Kidney Int 2001; 60: 358–363
   PubMed Web of Science ®Google Scholar
• Ischiropoulos H, Beckman JS. Oxidative stress and nitration in neurodegeneration: cause, effect, or association?. J Clin Invest 2003; 111: 163–169
   PubMed Web of Science ®Google Scholar
• McKhan G, Drachman D, Folstein M, Katzman R, Price C, Stardlan M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of the Department of Health and human Services task force of Alzheimer's disease. Neurology 1984; 34: 939–944
   PubMed Web of Science ®Google Scholar
• Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999; 56: 303–308
   PubMed Web of Science ®Google Scholar
• Frick B, Schrocksnadel K, Neurauter G, Wirletner B, Artner-Dworzak E, Fuchs D. Rapid measurement of total plasma homocysteine by HPLC. Clin Chim Acta 2003; 331: 19–23
   PubMed Web of Science ®Google Scholar
• Khoschsorur GA, Winklhofer-Roob BM, Rabl H, Auer T, Peng Z, Schaur RJ. Evaluation of a sensitive HPLC method for the determination of malondialdehyde, and application of the method to different biological materials. Chromatographia 2000; 52: 181–184
   Web of Science ®Google Scholar
• Hayashi T, Era S, Kawai K, Imai H, Nakamura K, Onda E, Yoh M. Observation for redox state of human serum and aqueous human albumin from patients with senile cataract. Pathophysiology 2000; 6: 237–243
   Google Scholar
• Lamprecht M, Greilberger J, Oettl K. Analytical aspects of oxidatively modified substances in sports and exercises. Nutrition 2004; 20: 728–730
   PubMed Web of Science ®Google Scholar
• Ahlskog JE, Uitti RJ, Low PA, Tyce GM, Nickander KK, Petersen R, Kokmen E. No evidence for systemic oxidative stress in Parkinson's or Alzheimer's disease. Mov Disord 1995; 10: 566–573
   PubMed Web of Science ®Google Scholar
• Kalman J, Kudchodkar BJ, Murray K, McConathy WJ, Juhasz A, Janka Z, Lacko AG. Evaluation of serum-lipid-related cardiovascular risk factors in Alzheimer's disease. Dement Geriatr Cogn Disord 1999; 10: 488–493
   PubMedGoogle Scholar
• Smith MA, Harris PLR, Sayre LM, Perry G. Iron accumulation in Alzheimer's disease is a source of redox-generated free radicals. Proc Natl Acad Sci USA 1997; 94: 9866–9868
   PubMed Web of Science ®Google Scholar
• Hensley K, Hall N, Subramaniam R, Cole P, Harris M, Aksenov M, Aksenova M, Gabbita SP, Wu JF, Carney JM, Lovell M, Markesbery WR, Butterfield DA. Brain regional correspondence between Alzheimer's disease histopathology and biomarkers of protein oxidation. J Neurochem 1995; 5: 2146–2156
   Google Scholar
• McGrath LT, McGleenon BM, Brennan S, McColl D, McILroy S, Passmore AP. Increased oxidative stress in Alzheimer's disease as assessed with 4-hydroxynonenal but not malondialdehyde. QJM 2001; 94: 485–490
   PubMed Web of Science ®Google Scholar
• Bermejo P, Martin-Aragon S, Benedi J, Susin C, Felici E, Gil P, Ribera JM, Villar AM. Peripheral levels of glutathione and protein oxidation as markers in the development of Alzheimer's disease from mild cognitive impairment. Free Radic Res 2008; 42: 162–170
   PubMed Web of Science ®Google Scholar
• Mattson MP, Guo Q, Furukawa K, Pedersen WA. Presenilins, the endoplasmatic reticulum and neuronal apoptosis in Alzheimer′s disease. J Neurochem 1998; 70: 1–14
   PubMed Web of Science ®Google Scholar
• Era S, Kuwata K, Imai H, Nakamura K, Hayashi T, Sogami M. Age-related change in redox state of human serum albumin. Biochim Biophys Acta 1995; 1247: 12–16
   PubMed Web of Science ®Google Scholar
• Soejima A, Matsuzawa N, Hayashi T, Kimura R, Ootsuka T, Fukuoka K, Yamada A, Nagesawa T, Era S. Alteration of redox state of human serum albumin before and after hemodialysis. Blood Purif 2004; 22: 525–529
   PubMed Web of Science ®Google Scholar
• Suzuki E, Yasuda K, Takeda N, Sakata S, Era S, Kuwata K, Sogami M, Miura K. Increased oxidized form of human serum albumin in patients with diabetes mellitus. Diab Res Clin Pract 1992; 18: 153–158
   PubMed Web of Science ®Google Scholar
• Lehmann M. Identification of cognitive impairment in the elderly: homocysteine is an early marker. Dement Geriatr Cogn Disord 1999; 10: 12–20
   PubMed Web of Science ®Google Scholar
• McCaddon A. Total serum homocysteine in senile dementia of Alzheimer type. Int J Geriatr Psychiatry 1998; 13: 235–239
   PubMed Web of Science ®Google Scholar
• Kado DM, Karlamangala AS, Huang MH, Troen A, Rowe JW, Selhub J, Seeman TE. Homocysteine versus the vitamins folate, B6 and B12 as predictors of cognitive function and decline in older high-functioning adults: MacArthur Studies of successful aging. Am J Med 2005; 118: 161–167
   PubMed Web of Science ®Google Scholar
• Kalmijn S, Launer LJ, Lindemans J, Bots ML, Hofman A, Breteler MM. Total homocysteine and cognitive decline in a community-based sample of elderly subjects: The Rotterdam Study. Am J Epidemiol 1999; 150: 283–289
   PubMed Web of Science ®Google Scholar
• Ravaglia G, Forti P, Maioli F, Vettori C, Grossi G., Bargossi AM, Caldarera M, Franzeschi C, Facchini A, Mariani E, Cavalli G. Elevated plasma homocysteine levels in centarians are not associated with cognitive impairment. Mech Ageing Dev 2000; 121: 251–261
   PubMedGoogle Scholar
• Mizrahi EH, Bowirrat A, Jacobsen DW, Korczyn AD, Traore F, Petot AJ, Lerner AJ, Debanne SM, Adunsky PM, DiBello PM, Friedland RP. Plasma homocysteine, vitamin B12 and folate in Alzheimer's patients and healthy Arabs in Israel. J Neurol Sci 2004; 227: 109–113
   PubMed Web of Science ®Google Scholar
• McGrath LT, McGleenon BM, Brennan S, McColl D, McIlroy S, Passmore AP. Increased oxidative stress in Alzheimer's disease as assessed with 4-hydroxynonenal but not malondialdehyde. Q J Med 2001; 94: 485–490
   Google Scholar